皮下而非静脉给予乌司奴单抗诱导治疗与相当的循环药物水平和早期临床应答相关:一项先导研究
这项先导研究纳入19例克罗恩病患者,采用皮下乌司奴单抗诱导(第0周180 mg、第1周90 mg、第2周90 mg,共360 mg分次给药),第8周谷浓度中位数为6.1 μg/mL(四分位距4-9.8 μg/mL),Harvey Bradshaw指数从第0周中位5显著改善至第8周中位1(P=0.002),粪便钙卫蛋白从533 μg/g降至278 μg/g(P=0.038)。作者认为皮下诱导的谷浓度与静脉诱导相当,结果支持在有静脉诱导障碍时皮下诱导可作为替代方案。
要点
- 皮下乌司奴单抗诱导第8周谷浓度中位6.1 μg/mL(四分位距4-9.8 μg/mL)。
- Harvey Bradshaw指数从第0周中位5降至第8周中位1(P=0.002)。
- 粪便钙卫蛋白从第0周中位533 μg/g降至第8周278 μg/g(P=0.038)。
核心结论
- 皮下或静脉给予乌司奴单抗诱导治疗的谷浓度相当,症状和粪便钙卫蛋白显著改善,结果支持在有静脉诱导障碍时皮下诱导可作为替代方案。
研究设计与样本
- 这项先导研究在单一学术中心纳入开始皮下乌司奴单抗治疗的克罗恩病患者,共19例。
- 皮下乌司奴单抗360 mg分次给药:第0周180 mg、第1周90 mg、第2周90 mg,评估至第8周的谷浓度。
主要发现
- 第8周乌司奴单抗谷浓度中位数为6.1 μg/mL(四分位距4-9.8 μg/mL)。
- Harvey Bradshaw指数从第0周中位5(四分位距2-8)改善至第8周中位1(四分位距0-3)(P=0.002)。
- C反应蛋白水平无显著变化,粪便钙卫蛋白显著改善:第0周中位533 μg/g,第8周278 μg/g(P=0.038)。
临床怎么用
- 作者认为,皮下诱导可作为存在静脉诱导障碍时的替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ustekinumab (USK) is licenced for intravenous induction and subcutaneous (S/C) maintenance in Crohn's disease. AIM: To evaluate ustekinumab trough concentrations and clinical response with exclusive subcutaneous ustekinumab induction. METHODS: Patients with Crohn's disease who initiated treatment with subcutaneous ustekinumab at a single academic centre were included in this pilot study. A dosage of 360 mg ustekinumab was given subcutaneously in divided doses; 180 mg at Week 0, 90 mg at Week 1 and 90 mg at Week 2, with corresponding ustekinumab trough concentrations assessed to Week 8. The primary outcome measures were trough serum ustekinumab levels and clinical remission at Week 8. Secondary outcome measures were trough serum ustekinumab levels at Week 1 & 2 and changes in C-reactive protein, albumin and faecal calprotectin at Week 8. RESULTS: Nineteen patients were included. Median Week 8 ustekinumab trough concentrations were 6.1 μg/mL (Inter-quartile range 4-9.8 μg/mL). There was a significant improvement in Harvey Bradshaw index from Week 0 (median HBI 5; interquartile range 2-8) to Week 8 (median HBI 1; interquartile range 0-3) (P = 0.002). C-reactive protein levels did not change significantly but faecal calprotectin improved significantly; median faecal calprotectin at Week 0 was 533 μg/g; at Week 8, it was 278 μg/g (P = 0.038). CONCLUSIONS: Ustekinumab trough concentrations are comparable whether ustekinumab induction treatment was administered subcutaneously or intravenously. A significant improvement in symptoms and faecal calprotectin was noted. These results support the use of subcutaneous induction as an alternative if there are barriers to intravenous induction.
引用
- Rowan CR, Keegan D, Byrne K, et al. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Aliment Pharmacol Ther. 2018. PMID: 29920697. doi:10.1111/apt.14834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。